The future of primary intraocular lymphoma (retinal lymphoma)

Ocular Immunology and Inflammation

Volumn 17, Issue 6, 2009, Pages 375-379

  Chan, Chi Chao ^a   Fisson, Sylvain ^b   Bodaghi, Bahram ^b  

^a NATIONAL EYE INSTITUTE   (United States)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Genetics; Imaging; Mouse model; Pathology; Primary intraocular lymphoma; Retinal lymphoma; Therapy

Indexed keywords

CYTARABINE; METHOTREXATE; RITUXIMAB;

B CELL LYMPHOMA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DNA POLYMORPHISM; DRUG MEGADOSE; EPIGENETICS; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; LYMPHOMA; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY INTRAOCULAR LYMPHOMA; RETINA TUMOR; SHORT SURVEY; T CELL LYMPHOMA;

ANIMALS; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; HUMANS; INFECTION; LYMPHOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETINAL NEOPLASMS;

EID: 72449141480     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273940903434804     Document Type: Short Survey

References (66)

1. Chan CC, Gonzalez JA. Primary Intraocular Lymphoma. New Jersey, London, Singapore, Beijing, Shanghai, Hong Kong, Taipei, Chennai World Scientific Publishing Co. Pte. Ltd., 2007.
2. Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Experiment Ophthalmol. 2008;36(6):564-578
3. Wakefield D, Zierhut M. Controversies in intraocular lymphoma. Ocul Immunol Inflamm. 2009;17(1):4-5.
4. Wakefield D, Zierhut M. Intraocular lymphoma: more questions than answers. Ocul Immunol Inflamm. 2009;17(1):6-10.
5. Mochizuki M, Singh AD. Epidemiology and clinical features of intraocular lymphoma. Ocul Immunol Inflamm. 2009;17(2):69-72.
6. Sen HN, Bodaghi B, Hoang PL, Nussenblatt R. Primary intraocular lymphoma: diagnosis and differential diagnosis. Ocul Immunol Inflamm. 2009;17(3):133-141
7. Coupland SE, Chan CC, Smith J. Pathophysiology of retinal lymphoma. Ocul Immunol Inflamm. 2009;17(4): 227-237
8. Cooper EL, Ricker JL. Malignant lymphoma of the uveal tract. Am J Ophthalmol. 1951;34:1153-1158
9. Tuaillon N, Chan CC. Molecular analysis of primary central nervous system and primary intraocular lymphoma. Curr Mol Med. 2001;1(2):259-272
10. Alizadeh A, Eisen M, Davis RE, et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol. 1999;64:71-78
11. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511
12. Nussenblatt RB, Chan CC, Wilson WH, et al. International Central Nervous System and Ocular Lymphoma Workshop. Ocul Immunol Inflamm. 2006;14(3):139-144
13. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95-107.
14. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385-389
15. Edwards AO, Ritter R, 3rd, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308(5720):421- 424
16. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular. Science. 2005;308(5720):419-421
17. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH). Proc Natl Acad Sci U S A. 2005;102(20): 7227-7232
18. Jakobsdottir J, Conley YP, Weeks DE, et al. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet. 2005;77(3):389-407.
19. Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related. Science. 2006;314(5801):992-993
20. Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science. 2006;314(5801):989-992
21. Hughes LB, Beasley TM, Patel H, et al. Racial or ethnic differences in allele frequencies of single-nucleotide. Ann Rheum Dis 2006;65(9):1213-1218
22. Ranganathan P, Culverhouse R, Marsh S, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX. J Rheumatol. 2008;35(4):572-579
23. Chan CC, Whitcup SM, Solomon D, Nussenblatt RB. Interleukin- 10 in the vitreous of primary intraocular lymphoma. Am J Ophthalmol. 1995;120(5):671-673
24. Whitcup SM, Stark-Vancs V, Wittes RE, et al. Association of interleukin-10 in the vitreous and cerebral spinal fluid and primary central nervous system lymphoma. Arch Ophthalmol. 1997;115:1157-1160
25. Wolf LA, Reed GF, Buggage RR, et al. Vitreous cytokine levels. Ophthalmology. 2003;110(8):1671-1672
26. Merle-Beral H, Davi F, Cassoux N, et al. Biological diagnosis of primary intraocular lymphoma. Br J Haematol. 2004;124(4):469-473
27. Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion ofprimary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2007;48(7):3253-3259
28. Chan CC, Shen D, Hackett JJ, et al. Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. Ophthalmology. 2003;110(2):421-426
29. Smith JR, Braziel RM, Paoletti S, et al. Expression of B-cellattracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood. 2003;101(3):815-821
30. Sen HN, Chan CC, Byrnes G, et al. Intravitreal methotrexate resistance in a patient with primary intraocular. Ocul Immunol Inflamm. 2008;16(1):29-33.
31. Ferreri AJ, Dell'Oro S, Capello D, et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol. 2004;126(5):657-664
32. Kube D, Hua TD, von Bonin F, et al. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin Cancer Res. 2008;14(12):3777-3784
33. Yu K, Martin R, Rothman N, et al. Two-sample comparison based on prediction error, with applications to candidate gene association studies. Ann Hum Genet. 2007;71(Pt 1): 107-118
34. Bogunia-Kubik K, Mazur G, Wrobel T, et al. Interleukin-10 gene polymorphisms influence the clinical course of non- Hodgkin's lymphoma. Tissue Antigens. 2008;71(2):146-150
35. Domingo-Domenech E, Benavente Y, Gonzalez-Barca E, et al. Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica. 2007;92(11):1475-1481
36. Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer. Apmis. 2007;115(10):1039-1059
37. Gronbaek K, Treppendahl M, Asmar F, Guldberg P. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy. Basic Clin Pharmacol Toxicol. 2008;103(5):389-396
38. Garcia-Manero G, Yang H, Kuang SQ, et al. Epigenetics of acute lymphocytic leukemia. Semin Hematol. 2009;46(1): 24-32.
39. Chu LC, Eberhart CG, Grossman SA, Herman JG. Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer. 2006;119(10):2487-2491
40. Chan CC, Shen DF, Whitcup SM, et al. Detection of human herpesvirus-8 and Epstein-Barr virus DNA in primary intraocular lymphoma. Blood. 1999;93(8):2749-2751
41. Shen DF, Herbort CP, Tuaillon N, et al. Detection of toxoplasma gondii DNA in primary intraocular B-cell lymphoma. Mod Pathol. 2001;14(10):995-999
42. Fardeau C, Lee CP, Merle-Béral H, et al. Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin's primary intraocular lymphoma. Am J Ophthalmol. 2009;147(5):886-894, 94 e1.
43. Pantanelli SM, Li Z, Fariss R, et al. Differentiation of malignant B-lymphoma cells from normal and activated. Cancer Res. 2009;69(11):4911-4917
44. Bessell EM, Hoang-Xuan K, Ferreri AJ, Reni M. Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer. 2007;43(7):1141-1152 (Pubitemid 46590731)
45. de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol. 1999;83(4):448-451
46. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109(9):1709-1716
47. Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of. Br J Ophthalmol. 2008;92(3):383-388
48. Sou R, Ohguro N, Maeda T, et al. Treatment of primary intraocular lymphoma with intravitreal methotrexate. Jpn J Ophthalmol. 2008;52(3):167-174
49. Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL. Neurology. 2008;71(17):1355-1360
50. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose. Lancet. 2009 [Epub September 18].
51. Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol. 2004;126(2):202-208 (Pubitemid 38961938)
52. Ferreri AJ, Blay JY, Reni M, et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol. 2002;13(4):531-538
53. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-174
54. Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina. 2009;29(2):129-132
55. Singh AD, Peereboom DM. Intraocular rituximab. Eye. 2007;21(12):1453-1454
56. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf. 2009.
57. de Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol. 2008;140(6):635-643
58. Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001;19(3):742-749
59. Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for. J Clin Oncol. 2008;26(15):2512-2518
60. Ferreri AJ, Crocchiolo R, Assanelli A, et al. High-dose chemotherapy supported by autologous stem cell transplantation. Leuk Lymphoma. 2008;49(11):2042-2047
61. Hochman J, Assaf N, Deckert-Schluter M, et al. Entry routes of malignant lymphoma into the brain and eyes in a mouse model. Cancer Res. 2001;61(13):5242-5247
62. Chan CC, Fischette M, Shen D, et al. Murine model of primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2005;46(2):415-419
63. Li Z, Mahesh SP, Shen de F, et al. Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma. Cancer Res. 2006;66(21):10586-10593
64. Touitou V, Daussy C, Bodaghi B, et al. Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. Invest Ophthalmol Vis Sci. 2007;48(7):3223-3229
65. Mineo JF, Scheffer A, Karkoutly C, et al. Using human CD20- transfected murine lymphomatous B cells to evaluate the. Invest Ophthalmol Vis Sci. 2008;49(11):4738-4745
66. Touitou V, Bodaghi B, de Kozak Y, et al. Animal models of intraocular lymphomas. Ophthalmic Res. 2008;40(3-4): 208-211